NCT06270147

Brief Summary

This clinical trial aims to determine the optimal timing for administering a Transversus Abdominis Plane (TAP) block in bariatric surgery, specifically investigating whether initiating TAP blocks at the beginning of surgery is more beneficial than at the end, which is the current practice. The study targets obese patients undergoing bariatric surgery, with a focus on reducing postoperative pain and opioid use. Key outcomes include recovery duration, pain levels, opioid consumption, and respiratory function. Successful results could establish early TAP block initiation as a standard practice, offering faster recovery, decreased opioid reliance, and reduced healthcare costs.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Nov 2024

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 6, 2024

Completed
15 days until next milestone

First Posted

Study publicly available on registry

February 21, 2024

Completed
9 months until next milestone

Study Start

First participant enrolled

November 21, 2024

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2025

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 28, 2025

Completed
Last Updated

November 25, 2024

Status Verified

November 1, 2024

Enrollment Period

2 months

First QC Date

February 6, 2024

Last Update Submit

November 22, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Opioid Consumption

    Opioid Consumption in the post- anesthetic recovery unit

    Immediately post-op

Secondary Outcomes (6)

  • Length of Stay

    immediately post-operative

  • Anesthesia requirements

    Intra-operatively

  • Sedation requirements

    post-operative up to 24 Hours

  • Nausea and vomiting

    post-operative up to 24 Hours

  • Respiratory Status

    immediately post-operative

  • +1 more secondary outcomes

Study Arms (2)

Early TAP block

EXPERIMENTAL

Patients in this group will receive TAP blocks at the beginning of the procedure

Drug: Bupivacaine-epinephrine

Late TAP block

ACTIVE COMPARATOR

Patients in this group will receive TAP blocks at the end of their procedure, which is the current standard practice.

Drug: Bupivacaine-epinephrine

Interventions

A total of 60ml of 0.25% Bupivacaine with Epinephrine, divided into 4 aliquots, will be administered laparoscopically at two locations per side along the anterior axillary line between the costal margin and the iliac crest. TAP block timing will be disclosed to the operating surgeon to ensure the correct solution is administered at the appropriate time.

Early TAP blockLate TAP block

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing primary bariatric surgery at St. Joseph's Healthcare Hamilton surgery including Sleeve Gastrectomy (SG) or Roux-en-Y Gastric Bypass Surgery (RYGB)
  • Patients \>18 Years of Age

You may not qualify if:

  • Patients undergoing a revisional bariatric surgery
  • Patients with a history of chronic pain or opioid use.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Joseph's Healthcare Hamilton - Charlton Campus

Hamilton, Ontario, L8N 4A6, Canada

RECRUITING

MeSH Terms

Conditions

Pain, Postoperative

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 6, 2024

First Posted

February 21, 2024

Study Start

November 21, 2024

Primary Completion

January 31, 2025

Study Completion

June 28, 2025

Last Updated

November 25, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

Locations